Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03986931 · ClinicalTrials.gov registry record · NA
A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting
A NA study, sponsored by Linnea Polgreen.
- Completed
- Registry status
- NA
- Development phase
- 535
- Enrollment target
NCT03986931: Completed NA study, sponsored by Linnea Polgreen.
NCT03986931 is a NA study that has completed, run by Linnea Polgreen. The registered enrollment target is 535 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03986931, a NA study, has completed, sponsored by Linnea Polgreen.
- COMPLETED
- Registry status
- NA
- Development phase
- 535 participants
- Enrollment target
Study Summary
Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. However, pharmacists are expensive, and in successful interventions, spent a substantial amount of time collecting home BP measurements. In this study, a proven pharmacist intervention will be added to a bidirectional texting program to determine if a combined pharmacist-bidirectional texting intervention is successful at decreasing subject BP and increasing subject BP treatment intensification in a cost-effective manner. This study will be a cluster-randomized, controlled trial of a new intervention.
Primary Outcome
The difference between the groups in the change from baseline to 12 months in systolic blood pressure in mm Hg.
Interventions
- OTHER Experimental: Pharmacist-Bidirectional Texting Group
- OTHER Active Comparator: Control Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2023-06-22 |
| Phase | NA |
What the finished NCT03986931 record still lists
NCT03986931 is an interventional study that assigns participants to a tested intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Experimental: Pharmacist-Bidirectional Texting Group is the first listed.
NCT03986931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03986931 about?
NCT03986931 is a clinical study titled "A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting". Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. However, pharmaci...
What is the current status of trial NCT03986931?
This trial is currently completed. It is a NA study. The enrollment target is 535 participants. The study started on 2020-02-25. Estimated completion is 2023-06-22.
What interventions are being tested in trial NCT03986931?
The interventions under investigation include: Experimental: Pharmacist-Bidirectional Texting Group (OTHER), Active Comparator: Control Group (OTHER).
Who is sponsoring clinical trial NCT03986931?
This trial is sponsored by Linnea Polgreen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03986931's enrollment target sits among peer trials
535 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI